Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8573566 | 0.83 | RAB9A (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL1406834 | 0.81 | NPC1 (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL4701434 | 0.81 | RAB9A (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL1458129 | 0.81 | ALDH1A1 (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL17895911 | 0.81 | CYP1A2 (0.46) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2671293 | 0.81 | CYP3A4 (0.46) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL8986609 | 0.80 | RAB9A (0.48) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL16229739 | 0.80 | RAB9A (0.48) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL561034 | 0.80 | RAB9A (0.62) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2315523 | 0.80 | RAB9A (0.48) | RAB9ANPC1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4031552-B1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4095138-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3555093-B1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-110072863-B | RIP1 kinase inhibitors and methods of use | 豪夫迈·罗氏有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4031552-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728975-A | Azole-fused pyridazin-3 (2H) -one derivatives | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1602647-A1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | FLT4, FLT1, KDR | RAB9A 1196/4885NPC1 1632/4885KDM4E 1027/4885 |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | GPR139, GPR119, GPR39 | RAB9A 460/4885NPC1 947/4885KDM4E 4254/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | RAB9A 460/4885NPC1 947/4885KDM4E 4254/4885 |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | FLT1, FLT4, PYM1 | RAB9A 2026/4885NPC1 1627/4885KDM4E 1303/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | RAB9A 2461/4885NPC1 2197/4885KDM4E 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.